<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2018-01-26'^^<http://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q151139>.
<http://www.wikidata.org/entity/Q151139> <http://www.w3.org/2000/01/rdf-schema#label> 'Frankfurt Stock Exchange'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Na8ec52bcb0904fa0aef116c3e71d640d <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '26.00'^^<http://www.w3.org/2001/XMLSchema#decimal>.
_:Na8ec52bcb0904fa0aef116c3e71d640d <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na8ec52bcb0904fa0aef116c3e71d640d <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€26.00 to €30.00'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:Na8ec52bcb0904fa0aef116c3e71d640d.
_:N88e3c11ea4fc4ca394eb95193cc0bf06 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '30.00'^^<http://www.w3.org/2001/XMLSchema#decimal>.
_:N88e3c11ea4fc4ca394eb95193cc0bf06 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N88e3c11ea4fc4ca394eb95193cc0bf06 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€26.00 to €30.00'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N88e3c11ea4fc4ca394eb95193cc0bf06.
<http://example.org/entity/#DermapharmHoldingSE> <http://www.w3.org/2000/01/rdf-schema#label> 'Dermapharm Holding SE'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/P946> '....... E000A2GS5D8'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/P249> '.......MP'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> <http://www.wikidata.org/entity/Q670792>.
<http://www.wikidata.org/entity/Q670792> <http://www.w3.org/2000/01/rdf-schema#label> 'Berenberg Bank'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q183>.
<http://www.wikidata.org/entity/Q183> <http://www.w3.org/2000/01/rdf-schema#label> 'Germany'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q183>.
<http://www.wikidata.org/entity/Q183> <http://www.w3.org/2000/01/rdf-schema#label> 'Germany'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q740419> 'forthefiscalyearsendedDecember 31, 2016, 2015 and 2014,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/hasAuditedFinancialStatement> 'from the audited consolidated financial statements of Dermapharm AG, theformerparententityofDermapharm,asofandforthefiscalyearsendedDecember 31, 2016, 2015 and 2014,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://www.wikidata.org/entity/Q176831> <http://www.w3.org/2000/01/rdf-schema#label> 'International Financial Reporting Standards'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidatedinterim financial statements'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q192907> '2017-09-30'^^<http://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q2481549> 'has not prepared any pro forma financial information'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q748250> 'has not prepared a profit forecast or profit estimate'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/hasAuditReport> 'without qualification.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LegalPersons/ProfitObjective> 'The Company intends to pursue the Offering and list its shares on the regulated market (regulierterMarkt) of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) and, simultaneously, on the subsegment with additional post admission obligations (Prime Standard) of the Frankfurt Stock Exchange(Frankfurter Wertpapierbörse) to receive the net proceeds from the Offering attributable to the Company and togain access to the capital markets.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'The Company currently intends to use the net proceeds attributable to the Companyas follows: approximately €35 million are to be spent on in-house developments andan upgrade of Dermapharm’s manufacturing facilities in Brehna, Germany, and anew manufacturing facility in Neumarkt am Wallersee, Austria, approximately€20 million for Dermapharm’s efforts to increase its international footprint (e.g., forfounding new enterprises in additional markets, hiring local sales managers and salespersonnel and similar investments) and between approximately €40 million and€50 million on the partial refinancing of a loan provided by Baden-WürttembergischeBank to partially finance the acquisition of Trommsdorff. The Company currentlyintends to spend any remaining net proceeds on general corporate purposes.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q7378915> 'True'^^<http://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesRestrictions/RegulationS> 'True'^^<http://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P12M'^^<http://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q1337875> 'An investment in the Company’s shares by an investor whose principal currency is not the Euromay be affected by exchange rate fluctuations.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N0e0c1ff88a884f079239b54403aa0076 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '269200000'^^<http://www.w3.org/2001/XMLSchema#decimal>.
_:N0e0c1ff88a884f079239b54403aa0076 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0e0c1ff88a884f079239b54403aa0076 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€269.2 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/placeholder/hasExpectedGrossProceeds> _:N0e0c1ff88a884f079239b54403aa0076.
_:N0ba0af0d7846456cbe714b342027cd85 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '259600000'^^<http://www.w3.org/2001/XMLSchema#decimal>.
_:N0ba0af0d7846456cbe714b342027cd85 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0ba0af0d7846456cbe714b342027cd85 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€259.6 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/placeholder/hasExpectedNetProceeds> _:N0ba0af0d7846456cbe714b342027cd85.
_:Na02c09ca781945dda06eaa553854c1fd <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '9600000'^^<http://www.w3.org/2001/XMLSchema#decimal>.
_:Na02c09ca781945dda06eaa553854c1fd <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na02c09ca781945dda06eaa553854c1fd <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€9.6 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q185142> _:Na02c09ca781945dda06eaa553854c1fd.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/Q1166072> 'The Selling Shareholder intends to pursue the Offering to receive the net proceeds from the Offeringattributable to the Selling Shareholder and to diversify its investments.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/hasDividendPolicy> 'The shareholders’ share of the Company’s profits is determined based on their respective interests inthe Company’s share capital. For a European company (Societas Europaea (SE)) with a two-tier managementand control system under European and German law such as the Company, the distribution of dividends for anygiven fiscal year and the amount and payment date thereof, are resolved by the Company’s shareholders’meeting (Hauptversammlung) of the subsequent fiscal year, based upon either a joint proposal by theManagement Board and the Company’s supervisory board (Aufsichtsrat (the “Supervisory Board”)) or uponthe Management Board’s or the Supervisory Board’s proposal. The shareholders’ meeting must be held withinthe first six months of each fiscal year.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'The Company is of the opinion that Dermapharm is in a position to meet the payment obligations thatbecome due within the next twelve months from the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'Dermapharm is a leader in branded pharmaceuticals for selected markets in Germany with anexpanding international footprint. It applies formulation and development expertise to the development,manufacture and marketing of a broad assortment of branded pharmaceuticals that are no longer patentprotected, holding approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than200 APIs. Dermapharm also offers a growing portfolio of other healthcare products such as cosmetics, foodsupplements, dietary products and medical devices. In addition, Dermapharm leverages its direct marketingexpertise by importing pharmaceuticals from other EEA Member States for resale in the German market inorder to profit from pricing differences between these markets.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/P452> 'pharmaceuticals'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FND/Parties/Parties/isAffectedBy> 'Changes in Tax Rates'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FND/Arrangements/Ratings/hasCompetitiveStrength> 'Highly experienced and committed management team with a proven track record'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/BusinessStrategy> 'Further optimize operations and market analysis for Dermapharm’s parallel import business'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://wikidata.org/entity/P8571> 'Warth & Klein Grant Thornton'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc62a7dd65ef34b8194a52e9fe7faebd9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '10200000'^^<http://www.w3.org/2001/XMLSchema#decimal>.
_:Nc62a7dd65ef34b8194a52e9fe7faebd9 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc62a7dd65ef34b8194a52e9fe7faebd9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€10.2 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/UnderwritingArrangement> _:Nc62a7dd65ef34b8194a52e9fe7faebd9.
<http://example.org/entity/#DermapharmHoldingSE> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> 'German generally accepted standards for the audit of financial statements'^^<http://www.w3.org/2001/XMLSchema#string>.
